Results 191 to 200 of about 41,710 (302)

Efficacy and Safety of Automated Insulin Delivery in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5091-5100, June 2026.
ABSTRACT Aims Studies evaluating automated insulin delivery (AID) in type 2 diabetes are limited in number and often conducted in small cohorts. We aimed to summarize efficacy and safety data through a systematic review and meta‐analysis. Materials and Methods We searched MEDLINE, PubMed, Web of Science, and CENTRAL databases and performed hand ...
Sergio Di Molfetta, Ludovico Di Gioia, Irene Caruso, Mariangela Caporusso, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino   +7 more
wiley   +1 more source

The Dipeptidyl Peptidase-4 Inhibitor Saxagliptin as a Candidate Treatment for Disorders of Consciousness: A Deep Learning and Retrospective Clinical Analysis. [PDF]

Neurocrit Care
Toker D, Chiang JN, Vespa PM, Schnakers C, Monti MM.   +4 more
europepmc   +1 more source

Combined Dipeptidyl Peptidase 4 Inhibitor and α-Glucosidase Inhibitor Treatment in Postprandial Hypoglycemia. [PDF]

Clin Diabetes, 2022
Broome DT, Kodali A, Phillips D, Makin V, Mendlovic D, Zimmerman RS.   +5 more
europepmc   +1 more source

Exertional heat stress and intestinal barrier injury: Does chronic disease add fuel to the fire?

Experimental Physiology, EarlyView.
Oliver R. Gibson, Zachary J. McKenna
wiley   +1 more source

Interrelationship Between Baseline HbA1c, SGLT‐2 Inhibitor Use and Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5217-5228, June 2026.
ABSTRACT Aims There is ongoing uncertainty about whether initiating sodium–glucose co‐transporter 2 inhibitor (SGLT‐2i) therapy in individuals with type 2 diabetes (T2D) who have elevated baseline HbA1c levels may lead to an additive or potentially synergistic increase in the risk of diabetic ketoacidosis (DKA). This systematic review and meta‐analysis
Samuel Seidu, Setor K. Kunutsor, Erwin Taguiam, Kamlesh Khunti   +3 more
wiley   +1 more source

A case report of dipeptidyl peptidase 4 inhibitor-related kidney disease combined with renal cancer. [PDF]

Front Nephrol
Kurihara S, Sawa N, Sumida K, Ikuma D, Oba Y, Mizuno H, Sekine A, Yamanouchi M, Hasegawa E, Suwabe T, Urakami S, Kono K, Kinowaki K, Ohashi K, Yamaguchi Y, Ubara Y.   +15 more
europepmc   +1 more source

Linagliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor, Reduces Physical and Behavioral Effects of Morphine Withdrawal. [PDF]

Molecules, 2022
Listos J, Listos P, Baranowska-Bosiacka I, Karpiuk A, Filarowska J, Łupina M, Słowik T, Zawiślak S, Kotlińska J.   +8 more
europepmc   +1 more source

Dipeptidyl peptidase‐4 inhibitor approaches

Journal of Diabetes, 2016
openaire   +1 more source

Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5240-5251, June 2026.
ABSTRACT Aims Although the American Diabetes Association (ADA) recently established a diagnostic algorithm for the early detection of liver fibrosis among high‐risk individuals, its implications for chronic kidney disease (CKD) risk stratification remain unclear.
Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim   +4 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading

Acta Dermato-Venereologica, 2018
Hiroyuki Takama, Makiko Yoshida, Kentaro Izumi, Takeshi Yanagishita, Jun Muto, Yuichiro Ohshima, Wataru Nishie, Hiroshi Shimizu, Masashi Akiyama, Daisuke Watanabe   +9 more
doaj   +1 more source